TIL Therapy: A Conversation with Dr. Allison Betof Warner

You may have heard of AMTAGVI, also known by the generic name lifileucel, a new therapy that recently earned FDA approval to treat patients with advanced melanoma in the second-line setting. AMTAGVI is the first individualized Tumor Infiltrating Lymphocyte (TIL) T cell immunotherapy to earn FDA approval for any cancer.
To learn more about the approval, MRA’s Chief Science Officer Dr. Joan Levy sat down with medical oncologist Dr. Allison Betof Warner of Stanford University. Dr. Betof Warner has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy.

[@user-cm7rn9hd6f]

Only 3%....😢